shares of biotechnology company revance therapeutics inc were lower afterhours monday following the companys announcement of a proposed underwritten public offering of 150 million of common stock the company said proceeds from the offering would be used to fund the commercialization of its products as well as for research and development and other purposes at 541 pm et the companys shares were trading 744 lower at 26 per share volume at the time topped 134000 shares the stock finished the days regular session with a 133 loss closing at 2809 per share revance said it is focused on developing and commercializing aesthetic and therapeutic offerings